The development of modern biologics has significantly expanded the therapeutic possibilities of monoclonal antibodies and related modalities. However, with increasing complexity, the requirements for their functional characterization have evolved as well. Beyond target binding, a central question has come into focus: Are biologics functionally performing as intended within the immune system? “Effector function in monoclonal […]
continue reading